cas 20028-53-9|| where to buy 2-Amino-5-chlorobenzaldehyde

Название продукции:2-Amino-5-chlorobenzaldehyde

IUPAC Name:2-amino-5-chlorobenzaldehyde

Упаковочная единица	Доступно для заказа	Цена ($)
CM251042-5g	in stock	şǆǠ
CM251042-10g	in stock	Ǡƴƚ
CM251042-25g	in stock	ǆȤǠ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 20028-53-9 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:20028-53-9; Молекулярная формула:C7H6ClNO; Точка плавления:-; Smiles-код:NC1=CC=C(Cl)C=C1C=O; Плотность:

: Номер в каталоге:CM251042; Молекулярная масса:155.58; Точка кипения:288.1°C at 760 mmHg; Номер Mdl:MFCD02093936; Хранение:Keep in dark place, inert atmosphere, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Olutasidenib; Rigel announces publication of data on REZLIDHIA(Olutasidenib) in post-venetoclax patients with mutant IDH1 AML in Leukemia & Lymphoma.
REZLIDHIA (Olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1), in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.